Hydrocortisone/neomycin/polymyxin b otic Disease Interactions
There are 4 disease interactions with hydrocortisone / neomycin / polymyxin b otic.
Neomycin (otic) (applies to hydrocortisone/neomycin/polymyxin b otic) perforated tympanic membrane
Major Potential Hazard, High plausibility.
Like other aminoglycosides, neomycin is potentially ototoxic, both to vestibular and to auditory functions. Therapy with neomycin otic preparations should be administered cautiously in patients with chronic otitis media or a perforated tympanic membrane. The risk of ototoxicity may be increased if medication enters the middle ear.
- "Product Information. Mycifradin (neomycin)." Emerson Laboratories (2001):
Otic agents (applies to hydrocortisone/neomycin/polymyxin b otic) perforated tympanic membrane
Major Potential Hazard, High plausibility. Applicable conditions: Chronic Otitis Media
The use of medications that are intended for the treatment of otitis externa or other conditions of the external ear canal should generally be avoided, or otherwise approached with caution, in patients with a perforated tympanic membrane due to the risk of toxicity from medication that may get into the middle ear. Caution is also advised in patients with longstanding, chronic otitis media because of the possibility of a perforated tympanic membrane in such patients.
- "Multum Information Services, Inc. Expert Review Panel"
- Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company (1996):
Otic corticosteroids (applies to hydrocortisone/neomycin/polymyxin b otic) viral infections
Major Potential Hazard, High plausibility. Applicable conditions: Herpes Simplex Otitis Externa, Herpes Zoster Otitis Externa
The use of otic preparations containing corticosteroids is contraindicated in patients with viral infections of the external canal including varicella and herpes simplex otitis externa. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. Normally, corticosteroids may be administered with caution provided it is accompanied by appropriate anti-infective agents. However, otic preparations that are currently available lack effective antiviral agents.
- American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Topical aminoglycosides (applies to hydrocortisone/neomycin/polymyxin b otic) burns
Moderate Potential Hazard, High plausibility. Applicable conditions: Burns - External
Topical aminoglycosides should not be used on serious burns. When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin. Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions. In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.
- "Product Information. Myciguent (neomycin topical)." Pharmacia and Upjohn (2001):
Hydrocortisone/neomycin/polymyxin b otic drug interactions
There are 21 drug interactions with hydrocortisone / neomycin / polymyxin b otic.
More about hydrocortisone / neomycin / polymyxin b otic
- hydrocortisone/neomycin/polymyxin b otic consumer information
- Check interactions
- Pricing & coupons
- Reviews (57)
- Side effects
- Dosage information
- During pregnancy
- Drug class: otic steroids with anti-infectives
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.